ReviewBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2022
Plant lectins as prospective antiviral biomolecules in the search for COVID-19 eradication strategies.
Review in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- The Biological Role of Enveloped Virus Glycosylation and Its Interactions with Antiviral Lectins.Advances in experimental medicine and biology · 2026Review
- Stilbenes in cancer therapy: insights into molecular targets, and advances towards clinical application.Medical oncology (Northwood, London, England) · 2025Review
- Plant Lectin, MoMo30, Pressures HIV-1 to Select for Variants with Deleted N-Linked Glycosylation Sites.Viruses · 2025Article
- Bioinformatic Selection of Mannose-Specific Lectins fromLife (Basel, Switzerland) · 2025Article
- Glycosylated SARs Cov 2 interaction with plant lectins.Glycoconjugate journal · 2024Review
- Effect of carbohydrates on the adhesion of Bordetella bronchiseptica to the respiratory epithelium in rabbits.Veterinary research communications · 2024Article
- Recent Insights into Glucose-Responsive Concanavalin A-Based Smart Hydrogels for Controlled Insulin Delivery.Gels (Basel, Switzerland) · 2024Review
- Mannose-specific plant and microbial lectins as antiviral agents: A review.Glycoconjugate journal · 2024Review
- Mannose-specific plant and microbial lectins as antiviral agents: A review.Glycoconjugate journal · 2024Review
- Health-promoting benefits of lentils: Anti-inflammatory and anti-microbial effects.Current research in physiology · 2024Review
- The Antiviral Potential of Algal Lectins.Marine drugs · 2023Review
- Article
- Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19.Life (Basel, Switzerland) · 2023Review
- Association of the Mannose-Binding Lectin 2 BB Genotype with COVID-19-Related Mortality.Life (Basel, Switzerland) · 2023Article
- Plant lectins as potent Anti-coronaviruses, Anti-inflammatory, antinociceptive and antiulcer agents.Saudi journal of biological sciences · 2022Review
- Legume Lectins with Different Specificities as Potential Glycan Probes for Pathogenic Enveloped Viruses.Cells · 2022Review
- Editorial: Synthesis and Bioactivities of Plant-Derived Biomolecules.Frontiers in plant science · 2022Article
- Investigation of the Binding of Lectins with Polymer Glycoconjugates and the Glycoconjugates Containing Silver Nanoparticles by Means of Optical Spectroscopy and Light Scattering.Polymer science. Series A, Chemistry, physics · 2022Article
- Role of ethno-phytomedicine knowledge in healthcare of COVID-19: advances in traditional phytomedicine perspective.Beni-Suef University journal of basic and applied sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lectins or clusters of carbohydrate-binding proteins of non-immune origin are distributed chiefly in the Plantae. Lectins have potent anti-infectivity properties for several RNA viruses including SARS-CoV-2. The primary purpose of this review is to review the ability of lectins mediated potential biotherapeutic and bioprophylactic strategy against coronavirus causing COVID-19. Lectins have binding affinity to the glycans of SARS-COV-2 Spike glycoprotein that has N-glycosylation sites. Apart from this, the complement lectin pathway is a "first line host defense" against the viral infection that is activated by mannose-binding lectins. Mannose-binding lectins deficiency in serum influences innate immunity of the host and facilitates infectious diseases including COVID-19. Our accumulated evidence obtained from scientific databases particularly PubMed and Google Scholar databases indicate that mannose-specific/mannose-binding lectins (MBL) have potent efficacies like anti-infectivity, complement cascade induction, immunoadjuvants, DC-SIGN antagonists, or glycomimetic approach, which can prove useful in the strategy of COVID-19 combat along with the glycobiological aspects of SARS-CoV-2 infections and antiviral immunity. For example, plant-derived mannose-specific lectins BanLac, FRIL, Lentil, and GRFT from red algae can inhibit and neutralize SARS-CoV-2 infectivity, as confirmed with in-vitro, in-vivo, and in-silico assessments. Furthermore, Bangladesh has a noteworthy resource of antiviral medicinal plants as well as plant lectins. Intensifying research on the antiviral plant lectins, adopting a glyco-biotechnological approach, and with deeper insights into the "glycovirological" aspects may result in the designing of alternative and potent blueprints against the 21st century's biological pandemic of SARS-CoV-2 causing COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.